Shield Therapeutics PLC
LSE:STX

Watchlist Manager
Shield Therapeutics PLC Logo
Shield Therapeutics PLC
LSE:STX
Watchlist
Price: 10.75 GBX -1.38% Market Closed
Market Cap: 114.1m GBX

Intrinsic Value

The intrinsic value of one STX stock under the Base Case scenario is 19.72 GBX. Compared to the current market price of 10.75 GBX, Shield Therapeutics PLC is Undervalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

STX Intrinsic Value
19.72 GBX
Undervaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Shield Therapeutics PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about STX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is STX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Shield Therapeutics PLC.

Explain Valuation
Compare STX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about STX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Shield Therapeutics PLC

Current Assets 41.4m
Cash & Short-Term Investments 10.8m
Receivables 23.8m
Other Current Assets 6.7m
Non-Current Assets 20.7m
PP&E 228k
Intangibles 19.5m
Other Non-Current Assets 1m
Current Liabilities 50m
Accounts Payable 16.1m
Accrued Liabilities 20.9m
Other Current Liabilities 13m
Non-Current Liabilities 26.9m
Long-Term Debt 26.9m
Efficiency

Free Cash Flow Analysis
Shield Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Shield Therapeutics PLC

Revenue
41.5m GBP
Cost of Revenue
-21.4m GBP
Gross Profit
20.1m GBP
Operating Expenses
-34.7m GBP
Operating Income
-14.6m GBP
Other Expenses
-6.6m GBP
Net Income
-21.2m GBP
Fundamental Scores

STX Profitability Score
Profitability Due Diligence

Shield Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

35/100
Profitability
Score

Shield Therapeutics PLC's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

STX Solvency Score
Solvency Due Diligence

Shield Therapeutics PLC's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
31/100
Solvency
Score

Shield Therapeutics PLC's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

STX Price Targets Summary
Shield Therapeutics PLC

Wall Street analysts forecast STX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STX is 16.32 GBX with a low forecast of 10.1 GBX and a high forecast of 24.15 GBX.

Lowest
Price Target
10.1 GBX
6% Downside
Average
Price Target
16.32 GBX
52% Upside
Highest
Price Target
24.15 GBX
125% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Shield Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for STX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one STX stock?

The intrinsic value of one STX stock under the Base Case scenario is 19.72 GBX.

Is STX stock undervalued or overvalued?

Compared to the current market price of 10.75 GBX, Shield Therapeutics PLC is Undervalued by 45%.

Back to Top